

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 11134-019-999	APPLICATION NO 10/789,165
	APPLICANT Collins <i>et al.</i>	
	FILING DATE February 26, 2004	GROUP 1624 To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CMS	A01	2002/0169159 A1	11/02	Medina <i>et al.</i>			


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CMS	A02	WO01/16114	3/01	PCT				
↓	A03	WO01/30768	5/01	PCT				
	A04	WO01/98278	12/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

--	--

EXAMINER Cecilia J. Jurek	DATE CONSIDERED 9/14/06
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
11134-019-999

APPLICATION NO
10/789,165

APPLICANT
Collins, *et al.*

FILING DATE
February 26, 2004

GROUP
~~1614~~ 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CMJ	B01	5,202,322	4/13/93	Allen <i>et al.</i>			
	B02	5,256,667	10/26/93	Allen <i>et al.</i>			
	B03	5,719,144	2/17/98	Hartman <i>et al.</i>			
	B04	5,756,502	5/26/98	Padia			
	B05	5,869,665	2/9/99	Padia			
	B06	5,908,930	6/1/99	Dow			
	B07	6,140,064	10/31/00	Loetscher <i>et al.</i>			
	B08	6,545,005	4/8/03	Baxter <i>et al.</i>			
	B09	6,605,632	8/12/03	Lesieur <i>et al.</i>			
	B10	6,794,379	9/21/04	Medina <i>et al.</i>			
	B11	20030134843	7/17/03	Lubisch <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CMJ	B12	International Search Report of PCT/US01/47850	8/26/02	PCT				
	B13	International Search Report of PCT/US04/05960	10/12/04	PCT				
	B14	EP 0481 614 A1	4/22/92	EPO				
	B15	WO92/01675	2/6/92	PCT				
	B16	WO97/04775	2/13/97	PCT				
	B17	WO98/13350	4/2/98	PCT				
	B18	WO98/26664	6/25/98	PCT				
	B19	WO99/58495	11/18/95	PCT				
	B20	WO01/057038	8/9/01	PCT				
	B21	WO01/19800 A2	3/22/01	PCT				
	B22	WO01/19800 A3	3/22/01	PCT				
	B23	WO01/62758	8/30/01	PCT				
	B24	WO01/77087	10/18/01	PCT				
	B25	WO02/28831	4/11/02	PCT				
	B26	WO02/083143	10/24/02	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CMJ	B27	Agostini, <i>et al.</i> , 1998 "Involvement of the IP-10 Chemokine in Sarcoid Granulomatous Reactions", <i>J. Immunol.</i> 161: 6413-6420.
-----	-----	--

CMJ	B28	Balashov <i>et al.</i> , 1999 "CCR5 ⁺ and CXCR3 ⁺ T Cells are Increased in Multiple Sclerosis and Their Ligands MIP-1 α and IP-10 are Expressed in Demyelinating Brain Lesions," <i>Proc. Natl. Acad. Sci. USA</i> , 96:6873-78.
	B29	Banker, <i>et al.</i> , 1996 "Prodrugs", <i>Modern Pharmaceutics, 3ed</i> Marcel Dekker, New York 596.
	B30	Bowdish <i>et al.</i> 2003 "Evaluation of An Oral CXCR3 Antagonist in a Rat Model of the Acute Allograft Rejection", <i>The Journal of the Heart and Lung Association</i> Vol. 22 Supplement 1 Page S162
	B31	Carter, <i>et al.</i> , 2002 "Chemokine Receptor Antagonism as an Approach to Anti-Inflammatory Therapy: 'Just Right' or Plain Wrong?", <i>Current Opin. Chem. Biol.</i> , 6: 510-525.
	B32	Cecil's Textbook of Medicine, 20 th Edition, Vol. 1 (a996), pages 1004-1010 (1996)
	B33	Cecil's Textbook of Medicine, 20 th Edition, Vol. 2, pages 1992-96 (1996)
	B34	Chabrier <i>et al.</i> Pubmed Abstract 10442086, also cited as <i>Cell. Mol. Life Sci.</i> 55/8-9 1029-35 (1999)
	B35	Chiang <i>et al.</i> , Pubmed Abstract 12898413, also cited as <i>Planta Med.</i> , 69/7, 600-4, (2003)
	B36	J.T. Coyle <i>et al.</i> , 1983 <i>Science</i> 219, 1184-90
	B37	Fife <i>et al.</i> , 2001 "CXCL10 (IFN- γ -Inducible Protein-10) Control of Encephalitogenic CD4 ⁺ T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis", <i>J. Immunol.</i> 166: 7617-7624.
	B38	Gerard, <i>et al.</i> , 2001 "Chemokines and Diseases", <i>Nature Immunology</i> , 2(2): 108-115.
	B39	Goldberg <i>et al.</i> , 2001 Pubmed Abstract 11437993, also cited as <i>Neuropathol. Appl. Neurobiol.</i> 27/2, 127-38.
	B40	Hancock <i>et al.</i> , 2000 "Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection," <i>J. Exp. Med.</i> , 192(10):1515-19..
	B41	Hancock <i>et al.</i> , 2001 "Donor-Derived IP-10 Initiates Development of Acute Allograft Rejection", <i>J. Exp. Med.</i> 193: 975-980
	B42	Liang, <i>et al.</i> , 2000 "Identification and Characterization of a Potent Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1", <i>The J. of Biol. Chem.</i> . 25(23): 19000-19008.
	B43	Liu <i>et al.</i> , 2001 "Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis", <i>J. Immunol.</i> 167: 4091-4097.
	B44	Melter <i>et al.</i> , 2001 "Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Cardiac Allograft Rejection", <i>Circulation</i> 104: 2558-2564.
	B45	Onuffer, <i>et al.</i> , 2002 "Chemokines, Chemokine Receptors and Small-Molecule Antagonists: Recent Developments", <i>Trends in Pharmacological Sciences</i> 23(10): 459-467.
	B46	Padia, J.K., <i>et al.</i> , "Design and synthesis of novel nonpeptide CCK-B receptor antagonists," <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , OXFORD, GB, vol. 7, no. 7, 8 April 1997, pp. 805-810.
	B47	Proudfoot, <i>et al.</i> , 2003 "Strategies for Chemokine Antagonists as Therapeutics", <i>Seminars in Immunology</i> . 15:57-65.
B48	Qin <i>et al.</i> , 1998 "The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions," <i>J. Clin. Invest.</i> 101(4): 746-54.	
B49	Rabin <i>et al.</i> , 1999 "Chemokine Receptor Responses on T Cells Achieved Through Regulation of Both Receptor Expression and Signaling," <i>The Journal of Immunology</i> . 162: 3840-50.	
B50	Rottman <i>et al.</i> , 2001 "Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin $\alpha\text{E}\beta 7$ in the Pathogenesis of Psoriasis Vulgaris", <i>Lab. Invest.</i> 81(3): 335-347.	
B51	Ruschpler <i>et al.</i> , 2003 "High CXCR3 Expression in nSynovial Mast Cells Associated with CXCL9 and CXCL10 Expression in Inflammatory Synovial Tissues of Patients with Rheumatoid Arthritis", <i>Arthritis Res. Ther.</i> 5: R241-R252.	
B52	Sasaki <i>et al.</i> , November 2002 "Blockade of CXCL10 Protects Mice From Acute Colitis and Enhances Crypt Cell Survival", <i>Eur. J. Immunol.</i> 32: 3197-31205.	
B53	Shields, <i>et al.</i> , 1999 "Chemokine and Chemokine Receptor Interactions Provide a Mechanism for Selective T Cell Recruitment to Specific Liver Compartments with Hepatitis C-Infected Liver", <i>J. Immunol.</i> 163: 6236-6243.	
B54	Sorensen <i>et al.</i> , 1999 "Expression of Specific Chemokines and Chemokine Receptors in the Central Nervous System of Multiple Sclerosis Patients", <i>J. Clinical Invest.</i> 103: 807-815.	
B55	Uckun <i>et al.</i> , 2001 "Structure Based Design of Novel Anticancer Agents", <i>Current Cancer Drug Targets</i> , 1, 59-71	
B56	Wells, <i>et al.</i> , 1999 "Chemokine Receptors and Their Antagonists in Allergic Lung Disease" <i>Inflamm. Res.</i> , 48: 353-362.	
B57	Wolff, Manfred E. "Burger's Medicinal Chemistry, 5ed Part 1", John Wiley & Sons, 1995, Pages 975-977.	
B58	Zhao <i>et al.</i> , 2002 Pubmed Abstract 121133984, also cited as <i>J. Immunol.</i> , 169/3 1556-60	
EXAMINER		Cecilia Jurele
DATE CONSIDERED		9-14-06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		